ACTRN12614000284662招募中未知
The Central Australian Heart Protection Study: A Randomised Trial of Nurse-Led, Family Based Secondary Prevention of Acute Coronary Syndromes.
Baker IDI Heart and Diabetes Institute0 个研究点目标入组 360 人开始时间: 2014年3月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit(—)
- 性别
- All
入选标准
- •All patients admitted to the Alice Springs Hospital with the admission diagnosis of ST elevation myocardial infarction (STEMI), Non ST segment elevation ACS, or angina.
- •Aged over 18 years
- •Able to provide informed consent
- •Resident of Central Australia
排除标准
- •Patients will be excluded if they do not survive to discharge, have a discharge diagnosis inconsistent with ACS, who are not residents of Central Australia (i.e. Interstate or international visitors), or who have a significant neurological/cognitive impairment that prevents informed consent being obtained
研究者
相似试验
招募中
Unknown
Evaluation of Cardioprotective Nutrition in people with Metabolic Syndrome and High Blood Pressure: a randomized clinical trialHyperglycemiaHypertensionRBR-9v9r6vjniversidade do Estado da Bahia - UNEB
已完成
不适用
Heart protection studyCoronary heart disease (CHD)Circulatory SystemChronic ischaemic heart diseaseISRCTN48489393Medical Research Council (MRC) (UK)20,000
招募中
3 期
Evaluation of the effects of the cardioprotective diet on prevention of the incidence of cardiotoxicitycardiotoxicity in patients with breast cancer receiving Anthracycline.Malignant NeoplasmsC00-C97IRCT20131218015860N7School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center,Shahid Behes60
招募中
Unknown
Verification of the cardioprotective effect of ARNI on hemodialysis patients with heart diseaseHemodialysis patients with chronic heart failureJPRN-UMIN000052905Inoue Hospital300
进行中(未招募)
1 期
A multi-center cardiac safety study of subjects who participated in Organon sponsored Phase 1 and Phase 2 completed and discontinued trials with Org 24448 (Protocols: 22601;22602;22603; 153001;153002;153003;153004, 29402; III.04.0311).SchizophreniaEUCTR2007-001611-32-NLV Organon295
